Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
16.23
+0.19 (1.18%)
At close: Aug 14, 2026, 4:00 PM EDT
16.21
-0.02 (-0.12%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Viatris Revenue
Viatris had revenue of $3.76B in the quarter ending June 30, 2026, with 4.88% growth. This brings the company's revenue in the last twelve months to $14.74B, up 4.40% year-over-year. In the year 2025, Viatris had annual revenue of $14.30B, down -2.98%.
Revenue (ttm)
$14.74B
Revenue Growth
+4.40%
P/S Ratio
1.26
Revenue / Employee
$491,243
Employees
30,000
Market Cap
18.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.30B | -439.40M | -2.98% |
| Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | 11.50B | 66.60M | 0.58% |
| Dec 31, 2018 | 11.43B | -473.80M | -3.98% |
| Dec 31, 2017 | 11.91B | 830.80M | 7.50% |
| Dec 31, 2016 | 11.08B | 1.65B | 17.47% |
| Dec 31, 2015 | 9.43B | 1.71B | 22.15% |
| Dec 31, 2014 | 7.72B | 810.50M | 11.73% |
| Dec 31, 2013 | 6.91B | 113.00M | 1.66% |
| Dec 31, 2012 | 6.80B | 666.28M | 10.87% |
| Dec 31, 2011 | 6.13B | 679.30M | 12.46% |
| Dec 31, 2010 | 5.45B | 357.74M | 7.02% |
| Dec 31, 2009 | 5.09B | -44.80M | -0.87% |
| Dec 31, 2008 | 5.14B | 2.96B | 135.80% |
| Dec 31, 2007 | 2.18B | 566.94M | 35.17% |
| Mar 31, 2007 | 1.61B | 354.66M | 28.21% |
| Mar 31, 2006 | 1.26B | 3.79M | 0.30% |
| Mar 31, 2005 | 1.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.32B |
| Haleon | 14.80B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
| Hims & Hers Health | 2.58B |
VTRS News
- 8 days ago - Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M - TheFly
- 8 days ago - Viatris Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Viatris Slides: Q2 2026 - Filings
- 8 days ago - Viatris Earnings release: Q2 2026 - Filings
- 8 days ago - Viatris Quarterly report: Q2 2026 - Filings
- 8 days ago - Viatris reports Q2 adjusted EPS 69c, consensus 60c - TheFly
- 8 days ago - Viatris raises FY26 adjusted EPS view to $2.45-$2.59 from $2.33-$2.47 - TheFly
- 9 days ago - Viatris Reports Second-Quarter 2026 Financial Results - PRNewsWire